Page 22 - Les Meilleurs doctors pour votre CT (tomodensitométrie) - TOP 575 des médecins

Le contenu respecte la Politique Éditoriale Bookimed et est examinée médicalement par

Fahad Mawlood

Nimet Dortcan

  • 4.5 Bien 234 avis
  • 35 années d'expérience
  • Turquie, Istanbul, Liv Hospital Ulus
  • Areas of Interests

    • General Neurology
    • Clinical Neurophysiological examinations (Electromyography, evoked potentials, electroencephalography, polysomnography)
    • Peripheral Nervous System Diseases
    • Muscle diseases
    • Epilepsy
    • Headache
    • Sleep and sleep disorders
    • Migraine botox and botulinum A toxin applications

    Education:

    • 1980-1985 Atatürk Elementary School
    • 1985-1988 Anamur High School
    • 1988-1991 Anamur High School
    • 1991-1998 Marmara University Faculty of Medicine in English
    • 2000- 2004 PTT Education and Research Hospital Neurology Clinic (Medical Specialization Student)
    • 2007-2010 Istanbul University Health Sciences Experimental Medicine Research Institute Electroneurophysiology Master's Program
    • 2012- Clinical Neurophysiology Sub-branch Specialist

    Experiences:

    • September 2023-Currently Haliç University Faculty of Medicine, Faculty Member
    • January 2023-Currently Hisar Intercontinental Hospital, Department of Neurology
    • 2014- August 2023 Bilgi University Health Sciences Vocational School Electroneurophysiology Department, Faculty Member
    • 2019- 2022 Ataşehir Private Avicenna Hospital, Neurology Department
    • 2009-2018 Fatih Sultan Mehmet Education and Research Hospital Neurophysiology Laboratory (Specialist Doctor)
    • 2007-2010 Istanbul University Health Sciences Experimental Medicine Research Institute Electroneurophysiology Master's Program
    • 2005-2006 Istanbul University Istanbul Faculty of Medicine Department of Neurology Electrodiagnostics Department EMG Laboratory
    • 2000-2004 PTT Education and Research Hospital Neurology Clinic (Specialist Student in Medicine)

     

  • Lire la suite
Laminectomie
$23,000 - $23,000
Thérapie par cellules souches
$6,750 - $7,250
Info

Dr Ayhan Ozturk

  • 5 Excellent 7 avis
  • 45 années d'expérience
  • Turquie, Istanbul, Liv Hospital Vadistanbul
  • Areas of Interests

    • Demyelinating Diseases and MS
    • Peripheral Neuropathy and Motor Neuron Disease (ALS)
    • Neuromuscular Junction Diseases (MG)

    Education 

    • M.Sc. Faculty of Medicine, Ondokuz Mayıs University  1990
    • Specialization in Medicine  Neurology,  Ankara Training and Research Hospital 1997
    • Minor Specialization  Clinical Neurophysiology, Medical Specialization Board 2011

    Experience

    • Doctor MoH Kastamonu and Samsun Health Center No. 7 1990-1992
    • Dr. Res.Assist. Ankara Training and Research Hospital Neurology Clinic 1992-1997
    • Assoc. Dr. Abant İzzet Baysal University Düzce Faculty of Medicine 1999-2006
    • Assoc.Dr. Duzce University Faculty of Medicine 2007-2011
    • Prof.Dr  Duzce University Faculty of Medicine  2011-
  • Lire la suite
Stimulation du nerf vague
$22,000 - $22,000
Chimiothérapie
$3,000 - $3,500
Info

Dr Murat Ayhan

  • 5 Excellent 7 avis
  • 35 années d'expérience
  • Turquie, Istanbul, Liv Hospital Vadistanbul
  • Areas of Interests

    • Breast cancer
    • Lung cancer
    • Colorectal cancers
    • Gynecological and urogenital cancers
    • Molecular Oncology

    Education:

    • Kızıltepe Anatolian High School 2001
    • Dicle University Faculty of Medicine 2007
    • Istanbul Medeniyet University Göztepe Training and Research Hospital 2014
    • Kartal City Hospital 2021
    • Associate Professor of Medical Oncology 2023

    Experience:

    • Liv Hospital Ulus
    • Adıyaman University Training and Research Hospital
    • Istanbul Umraniye Training and Research Hospital
    • Istanbul Umraniye Training and Research Hospital

    Research:

    • Phase II, Randomized, Open-Label, Multicenter Study to Comparatively Evaluate the Efficacy and Safety of GDC-9545 and Physician-Preferred Endocrine Monotherapy in Previously Treated, Estrogen Receptor Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer Patients, Other ( International), Dr. Murat Ayhan
    • Phase III, Randomized, Evaluating the Efficacy and Safety of Palbociclib and Fulvestrant with Gdc-0077 Compared with Placebo in Patients with Pik3ca-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer. Double Blind, Placebo Controlled Study, Other (International), Dr. Murat Ayhan
    • Randomized, Multicenter, Phase Ib/III Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Atezolizumab Compared to Intravenous Atezolizumab in Patients with Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer, Other (International) Dr. Murat Ayhan
    • Randomized, Controlled, Multicenter, Open-Label Study Including Observation Follow-Up for PSMA-PET-Negative Patients, Investigating the Efficacy and Safety of Addition of Apalutamide to Radiotherapy and LHRH Agonist in PSMA-PET-Positive High-Risk Hormone-Sensitive Prostate Cancer Patients, Other (International) Dr. Murat Ayhan
    • Biomarker Study to Identify Patients with Advanced Stage Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations-42756493BLC0002, Other (International), Dr. Murat Ayhan
    • Publications:
    • Ayhan M, Turan N, Köstek O, et all. Does the efficacy of regorafenib differ in chemotherapy refractory metastatic colorectal cancer patients who had mucinous pathology compared to those who had non-mucinous pathology? Curr Probl Cancer. 2021 Jun;45(3):100670. doi: 10.1016/j.currproblcancer.2020.100670.
    • Ayhan M, Odabas H, Turan N, et all. Factors affecting the mortality rate of patients with cancer hospitalized with COVID-19: a single center's experience. J Chemother. 2021 Nov;33(7):499-508. doi: 10.1080/1120009X.2021.1923153.
    • Ayhan M, Laçin Ş, Özyükseler DT, et all. Does systemic anti-tumor therapy increase COVID-19 risk in patients with cancer? J Oncol Pharm Pract. 2021 Sep;27(6):1461-1467. doi: 10.1177/10781552211015762.
    • Ayhan M, Abamor E, Coban Kokten S, et al. Value of FDG PET/CT in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer. EJMI 2022;6(2):165–175.
    • Ayhan M, Terzioglu K. Experience With Rapid Drug Desensitization With Chemotherapeutics; A SingleCentre Retrospective Study. EJMI 2021;5(3):380–387.
    • Doğan A, AYHAN M. Survival analysis of patients with triple-negative breast cancer: a single-center experience. Journal of Oncological Sciences, 8(2), 94-99., Doi: 10.37047/jos.2022-89749
    • Terzioğlu K, Ayhan M. Comparative Assessment of Platinum Salts and Taxane Group Hypersensitivity Reactions, The Role of Skin Tests in Diagnosis? J Oncol Pharm Pract. 2021 Nov 30:10781552211050084. doi: 10.1177/10781552211050084.
    • Tacar SY, Selcukbiricik F, Yilmaz M, Erturk K, Murat Sarici A, Gulturk I, Ayhan M, Tural D. Nivolumab for metastatic uveal melanoma: a multicenter, retrospective study. Melanoma Res. 2021 Oct 1;31(5):449-455. doi: 10.1097/CMR.0000000000000744.
    • Özyurt E, Özçelik S, Sürmeli H, Çelik M, Ayhan M, Özçelik M. Side effects of immune-checkpoint inhibitors: Can multiple side effects be seen in a patient? J Oncol Pharm Pract. 2022 Mar;28(2):462-465. doi: 10.1177/10781552211038136.
    • Dülgar Ö, Öven BB, Atcı MM, Arıkan R, Ay S, Ayhan M, Selvi O, Ozyukseler DT, Bayram E, Özcan E, Yasin Aİ, Gümüş M. Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy? Expert Rev Anticancer Ther. 2022 Jul;22(7):773-780. doi: 10.1080/14737140.2022.2076670.
    • Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study. J Cancer Res Clin Oncol. 2022 Jun;148(6):1501-1508. doi: 10.1007/s00432-021-03748-7.
    • Volume I, Kucukarda A, Atcı MM, Ayhan M, et all. Efficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world study. Tumori. 2022 Feb;108(1):19-25. doi: 10.1177/03008916211037739.
    • Dogan I, Ayhan M, Gurbuz M, et all. The frequency and prognostic significance of ABO/Rh blood groups in male breast cancer patients: A multicenter study. Medicine (Baltimore). 2022 Sep 2;101(35):e30147. doi: 10.1097/MD.0000000000030147.
    • Ozcelik M, Oyman A, Cil I, Duzgun O, Ozkan OF, Ayhan M. Cytoreductive Surgery versus Systemic Chemotherapy alone in Isolated Peritoneal Carcinomatosis of Colorectal Origin. J Coll Physicians Surg Pak. 2021 Nov;31(11):1308-1313. doi: 10.29271/jcpsp.2021.11.1308.
    • Başoğlu T, Sakin A, Erol C, Ayhan M, et all. Real life experienceof patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study. J Chemother. 2022 May 17:1-8. doi: 10.1080/1120009X.2022.2073159.
    • Özdemir Ö, Zengel B, Yildiz Y, Ayhan M, et all. The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study. Anticancer Drugs. 2022 Aug 1;33(7):663-670. doi: 10.1097/CAD.0000000000001310.
    • Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study). J Cancer Res Clin Oncol. 2022 Sep 1. doi: 10.1007/s00432-022-04252-2.
    • Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study. Future Oncol. 2022 Jul;18(23):2573-2582. doi: 10.2217/fon-2022-0083.
    • Topcu A, Atci MM, Secmeler S, Besiroglu M, Ayhan M, Ozkan M, Bozkurt O, Urakci Z, Ay S, Geredeli C, Yasin AI, Turk HM. Efficacy of trastuzumab and potential risk factors on survival in patients with HER2-positive metastatic gastric cancer. Future Oncol. 2021 Nov;17(31):4157-4169. doi: 10.2217/fon-2021-0398.
    • Bilgin B, Sendur MAN, Yucel S, Ayhan M, et all. Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study. J Cancer Res Clin Oncol. 2021 Jul;147(7):2145-2152. doi: 10.1007/s00432-020-03501-6.
    • Atci MM, Akagunduz B, Demir M, Arikan R, Ay S, Ozer M, Ayhan M, Cil I, Demir N, Ozyurt N, Karakaya G, Cevik GT, Onder AH, Selvi O, Sakin A. The impact of adjuvant oxaliplatin and tumor sidedness on the overall survival of stage IIB colon cancer patients: a multicentre study. J Chemother. 2023 Feb;35(1):19-28. doi: 10.1080/1120009X.2022.2040770.
    • Tataroglu Ozyukseler D, Ay S, Turan M, Alkan G, Ayhan M, Surmeli H, et al. The Systemic Inflammation Response Index as a Prognostic Marker in Advanced Pancreatic Cancer. EJMI 2022;6(3):367–373.
    • Yıldız F, Ayhan M, Demir H, et all. Comparing the efficacy of cabazitaxel in secondline and third-Line treatment of metastatic castration-resistant prostate cancer: a multi-center experience from Turkey. International Journal of Contemporary Medical Research, 7(9), 112-116.,Doi: 10.21276/ijcmr.2020.7.9.30
    • Terzioğlu K, Ayhan M. Distribution of allergens detected on patch tests of patients with allergic contact dermatitis and investigation of their atopic background. Annals of Medical Research, 29(5), 422-426., doi: 10.5455/annalsmedres.2021.07.490
    • Arikan R, Atci MM, Ay S, Ayhan M, et all Prognostic significance of mucinous histology in left sided metastatic colorectal cancers with wild type RAS and evaluation of backbone chemotherapy regimens. Oncol Lett. 2023 Apr 5;25(5):208. doi: 10.3892/ol.2023.13795.
    • Almuradova E, Yalcin S, Arıkan R, Ayhan M, Demir H, Cevik GT, Karaca M, Petekkaya I, Karabulut B. Survival of Patients With Metastatic Rectum Cancer Who Underwent Metastasectomy Following Conversion Chemotherapy Sans Pelvic Radiotherapy: A Turkish Oncology Group Study. Cureus 2023 May 17;15(5):e39119. doi: 10.7759/cureus.39119.
    • Topcu A, Besiroglu M, Atci MM, Ayhan M, et all. Second-line Therapy after Trastuzumab Failure in HER2-Positive Metastatic Gastric Cancer: A Real-life Data. EJMI 2023;7(2):153–161. DOI: 10.14744/ejmi.2023.22720
    • Book Writing:
    • Drug interactions and side effects of targeted agents, Section name: (Small molecule tyrosine kinase inhibitors; ROS-1 targeted therapies (Crizotinib, Seritinib)) (2021)., AYHAN MURAT, Turkish Clinics Journal of Medical Sciences, Editor: Mehmet Aliustaoglu, Publishing number:1, Number of Pages 92, ISBN:978-625-401- 466-6, Turkish
    • Approach to gastrointestinal stromal tumors and neuroendocrine tumors, Department name: (Medical approach in primary non-gastrointestinal neuroendocrine tumors) (2020)., AYHAN MURAT, Akademisyen Yayınevi, Editor: Anılır Ender, Number of editions: 1, Number of Pages 382, ISBN: 9786052585719, Turkish
    • Internal medicine emergencies, Department name: (Oncological emergencies) (2022)., YILDIRIM SEDAT, AYHAN MURAT, Efe Academic Publishing, Editor: Serdar Olt, Number of editions: 1, Number of Pages 232, ISBN: 978-625-8324-66- 2, Turkish
    • Physicians' chemotherapy cancer drug manual 2020, Section name: (Common chemotherapy regimens in clinical practice) (2022)., SÜMBÜL AHMET TANER, ALKAN ALI, AKSOY ASUDE, AYHAN MURAT, et all, Türkiye Klinikleri Journal of Medical Sciences, Editor: EDWAR CHU, VINCENT T. DEVITA, SAADDETIN KILIÇKAP, CEMIL BILIR, SELÇUK SEBER, Number of editions: 1, Number of pages 772, ISBN: 978-625-401-290- 7, Turkish (Book Translation)

     

  • Lire la suite
Stimulation du nerf vague
$22,000 - $22,000
Chimiothérapie
$3,000 - $3,500
Info

Mehmet Alpay Cal

  • 4.5 Bien 234 avis
  • 35 années d'expérience
  • Turquie, Istanbul, Liv Hospital Ulus
  • Areas of Interests

    • Neuro-oncological surgery
    • Spinal Surgery
    • Pediatric Neurosurgery
    • Peripheral Nerve Surgery
    • Functional Neurosurgery and Algology

    Education:

    • Istanbul University, Faculty of Medicine
    • Istanbul Okmeydani Training and Research Hospital

    Experience:

    • Liv Hospital Ulus
    • Sisli Kolan Hospital
    • Prof.Dr.Cemil Taşcıoğlu City Hospital
    • Ardahan State Hospital

    Research:

    • Tumor markers and other laboratory findings in brain tumors
    • Antiepileptic drugs in operated brain tumors
    • Cervical corpectomy techniques
    • Pre-emptive analgesia in spine surgeries

    Publications:

    • Uysal E, Cine HS, Yavuz AY, Cal MA. Impact of subventricular zone interaction on clinical outcomes in patients with intracerebral hematoma. Experimental Biomedical Research, 2024;7(3): 117–126. https://doi.org/10.30714/j-ebr.2024.215
    • Çal MA, Yangı K. A Single-center Study Comparing Volumetric and Morphometric Measurements of Chiari Malformation in the Turkish Population. Eur Arc Med Res.2024 Mar;40(1):50-56. doi:10.4274/eamr.galenos.2024.24892.
    • Avcı İ, Başkurt O, Şeker S, Kurtuluş Y, Çal MA. Rapid Recurrence of Glioblastoma After 12 Days Despite Gross Total Resection. Eur Arc Med Res.2024 Mar;40(1):62-65. doi:10.4274/eamr.galenos.2024.48615.
    • Play MA. The relationship between vertebral compression rates and systemic inflammatory scores in osteoporotic vertebral fractures. Eur Rev Med Pharmacol Sci. 2024;28(3):959-968. doi:10.26355/eurrev_202402_35333
    • Çal MA, Gök H. Retrospective Evaluation of the Effect of Surgery and CyberKnife on Recurrence and Neurological Deficits in Cases Diagnosed as Vestibular Schwannoma. Haydarpasa Numune Med J.2023;63 (1), 62 ‑67.doi:10.14744/hnhj.2022.45712
    • Uysal E, Çal MA, Cine HS. The use of vancomycin powder in the compound depressed skull fractures. Clin Neurol Neurosurg. 2023;225:107570. doi:10.1016/j.clineuro.2022.107570
    • Gök H, Şeker S, Peker HO, Çal MA, Altay T, Çelik S. A rare case report: Cervical subcutaneous and mediastinal emphysema due to mastoid fracture. A rare case report: Cervical subcutaneous and mediastinal emphysema due to mastoid fracture. Ulus Travma Emergency Surgery Journal . 2020;26(2):328 ‑330. doi:10.14744/tjtes.2019.02828
    • Çınar N,Karaoğlan A,Midi A,Çal MA,Kelten B,Çakmak MA,Şahin Ş. Neuroprotective effect of ziprasidone: Preliminary results compared to haloperidol. J. Exp. Clin. Med ., 2014; 31:71 ‑75. doi : 10.5835/jecm.omu.31.02.002
    • Karaoglan A, Cal MA, Orki A, Arpaozu BM, Colak A. Pneumorrhachis associated with bronchial asthma , subcutaneous emphysema and pneumomediastinum . Turkish Neurosurg . 2011;21(4):666 ‑668.
    • Kelten B, Karaoğlan A, Cal MA, Akdemir O, Karancı T. Human immunodeficiency Bilateral epidural puncture in a patient infected with the virus Hematoma : Case report [ Bilateral epidural hematoma in a patient with Human immunodeficiency virus infection : a case report ]. Ulus Trauma Emergency Surgery Journal . 2013;19(3):267 ‑270. doi: 10.5505 /tjtes.2013.49799
    • Karaoglan A, Akdemir O, Cinar N, et al. Correlation between leptin and pro- ‑inflammatory cytokines in cortical contusion injury model. Ulus Trauma Emergency Surgery Journal . 2011;17(4):298 ‑302. doi: 10.5505 /tjtes.2011.69077
    • Cal MA, Kelten B, Akbas A, Akdemir O, Karaoglan A. Coexistence of spinal lipoma, ependymal cyst and dermoid cyst in neighboring localizations in context medullaris : A case report . HealthMed . 2013; 7(12):3227
    • Canpolat A, Duman H, Akbaş A, Çal MA, Akdemir AO. Diffuse dysphagia and myeloradiculopathy presenting idiopathic skeletal hyperosteosis ( Forestier Disease). TC Maltepe University Medical Faculty Journal.2012;4(2),14 ‑17
    • Karaoglan A, Kelten B,Akdemir AO,Çal MA. Lumbar spine presenting with radiculopathy spinal Chondroma : Case report. TC Maltepe University Medical Faculty Journal. 2011;3(3),28 ‑30
    •  
    • Istanbul Medical Chamber
    • Turkish Neurosurgery Association
       
  • Lire la suite
Laminectomie
$23,000 - $23,000
Thérapie par cellules souches
$6,750 - $7,250
Info

Dr Selami Sozubir

  • 4.5 Bien 234 avis
  • 35 années d'expérience
  • Turquie, Istanbul, Liv Hospital Ulus
  • Domaines d'intérêt

    • Chirurgie reconstructive urogénitale pédiatrique
    • Hypospadias
    • Circumcision
    • Chirurgie oncologique
    • Anomalies congénitales du système urinaire supérieur et inférieur
    • Chirurgie du nouveau-né
    • Chirurgie abdominale pédiatrique

    Formation
     

    • 1997 - Université 19 Mayıs
    • 1998 - Congrès national de chirurgie pédiatrique, Meilleure étude de recherche
    • 2001 - Université Kocaeli
    • 2007 - Gouvernement du Kosovo
    • 2009 - Université Yeditepe
    • 2009 - Congrès d'Arabie Saoudite, Meilleure étude clinique

    Expérience
     

    • Lycée FMV Işık
    • Faculté de médecine de l’Université d’Istanbul Cerrahpaşa
    • Université Ondokuz Mayıs
    • Hôpital pour enfants Zeynep Kamil
    • Faculté de médecine de l’Université Kocaeli
    • UT Southwestern Medical Center, urologie pédiatrique, Dallas, USA
    • Centre médical de l’Université Ege, urologie pédiatrique
    • Université Yeditepe

    Le Prof. Dr. Selami Sozubir est l’auteur de 65 publications scientifiques, ayant reçu plus de 11 000 lectures et près de 1 000 citations, ce qui témoigne de sa contribution importante dans le domaine de la chirurgie et de l’urologie pédiatriques.

  • Lire la suite
Laminectomie
$23,000 - $23,000
Thérapie par cellules souches
$6,750 - $7,250
Info

Hamit Aytar

  • 4.4 Bien 32 avis
  • 17 années d'expérience
  • Turquie, Istanbul, Emsey Hospital
Chirurgie du cancer de l'estomac
$14,500 - $20,000
Chimiothérapie intrapéritonéale hyperthermique (HIPEC)
$28,000 - $47,000
Colectomie (résection du gros intestin)
$11,000 - $16,000
Info

Hasan Turgut

  • 4.4 Bien 32 avis
  • 14 années d'expérience
  • Turquie, Istanbul, Emsey Hospital
Chirurgie du cancer de l'estomac
$14,500 - $20,000
Chimiothérapie intrapéritonéale hyperthermique (HIPEC)
$28,000 - $47,000
Colectomie (résection du gros intestin)
$11,000 - $16,000
Info

Meryem Keceli Basaran

  • Nouveau
  • 19 années d'expérience
  • Turquie, Istanbul, Biruni University Hospital
  • Éducation

    Médecin : Centre de santé n°1 Kilis Merkez, 2006-2008
    Médecin assistant : Faculté de médecine de l'Université de Mersin, 2009-2013
    Médecin spécialiste : Hôpital d'État de Bingöl Genç, 2013-2014
    Assistant mineur : Faculté de médecine de l'Université d'Akdeniz, 2014-2017
    Spécialiste mineur : Hôpital régional de formation et de recherche d'Erzurum, 2017-2018
    Spécialiste en médecine interne : Hôpital de formation et de recherche de Gaziosmanpaşa, 2018-2020
    Spécialiste traitant : Başakşehir Çam et hôpital municipal de Sakura, 2020-2022
    Professeur agrégé : Başakşehir Çam et hôpital municipal de Sakura, 2023
    Professeur agrégé : Hôpital Medicalpark Gaziosmanpaşa de l'Université Istinye, 2023-2024

    Adhésions scientifiques

    Société turque de pédiatrie
    Société turque de gastroentérologie, d'hépatologie et de nutrition pédiatriques
    ESPGHAN - Société européenne de gastroentérologie, d'hépatologie et de nutrition pédiatriques.

    Intérêts médicaux


    • -Syndrome du côlon irritable (sans repos)
    • -Allergies alimentaires associées au système digestif
    • -Constipation, incontinence fécale
    • -Diarrhée aiguë et chronique, malabsorption
    • -Douleurs abdominales chroniques
    • -Reflux gastro-œsophagien
    • - Maladie cœliaque
    • -Colite ulcéreuse, maladie de Crohn
    • -Traitement avant et après transplantation hépatique
    • - Pancréatite aiguë et chronique


  • Lire la suite
Tomothérapie
$8,440 - $14,140
Curiethérapie
$10,000 - $12,000
Info

Seda Turgut

  • 4.5 Bien 234 avis
  • 35 années d'expérience
  • Turquie, Istanbul, Liv Hospital Ulus
  • Areas of Interests

    • Pituitary Diseases
    • Thyroid Diseases
    • Obesity
    • Diabetes
    • Female and Male Reproductive System Diseases
    • Parathyroid Diseases
    • Adrenal Gland Diseases
    • Osteoporosis and Metabolic Bone Diseases

    Education:

    • Hacettepe University Faculty of Medicine
    • Bezmialem Foundation University
    • Health Sciences University Bakirkoy Dr. Sadi Konuk Training and Research Hospital
    • Cleveland Clinic, The Endocrinology and Metabolism Institute observer physician
    • University of Piemonte Orientale, SCDU Endocrinology, Italy, observer physician
       

    Experience:
     

    • Mehmet Akif Inan Training and Research Hospital
    • Bakirkoy Dr. Sadi Konuk Training and Research Hospital
    • Bezmialem Vakif University Hospital
    • Malatya State Hospital
  • Lire la suite
Laminectomie
$23,000 - $23,000
Thérapie par cellules souches
$6,750 - $7,250
Info

Fikret Baskan

  • Nouveau
  • 16 années d'expérience
  • Turquie, Istanbul, Biruni University Hospital
  • Éducation

    Licence Université Technique de Karadeniz 2001

    Doctorat : Hôpital de formation et de recherche Izmir Tepecik Neurochirurgie 2009

    Expérience

    Centre de santé Konya Doğanhisar Başköy 2001-2002

    Hôpital de formation et de recherche d'Izmir Tepecik 2004-2010

    Hôpital d'État d'Agri (Service obligatoire) 2010-2011

    Hôpital d'État d'Arnavutkoy 2011-2012

    Bakirkoy Sadi Konuk EAH 2012-2014

    Hôpital de formation et de recherche Kanuni d'Istanbul 2015-2020

    Hôpital municipal de Başakşehir çam Sakura 2020-2024

    En 2009, j'ai terminé ma formation de spécialité en neurochirurgie et neurochirurgie à l'hôpital de formation et de recherche d'Izmir Tepecik et j'ai travaillé comme médecin spécialiste à Istanbul Bakırköy Sadi Konuk EAH, Kanuni EAH et Başakşehir Çam et Sakura City Hospital affiliés à l'Université des sciences de la santé. Je travaille dans le domaine de la neurochirurgie pédiatrique depuis 9 ans. En 2024, j'ai commencé à travailler comme membre du corps professoral au département de neurochirurgie et de neurochirurgie de l'Université de Biruni.

    Adhésion scientifique

    Adhésion à la Société turque de neurochirurgie
    Adhésion au groupe de neurochirurgie pédiatrique
    Association médicale turque

  • Lire la suite
Tomothérapie
$8,440 - $14,140
Curiethérapie
$10,000 - $12,000
Info

Omer Dogru

  • Nouveau
  • 19 années d'expérience
  • Turquie, Istanbul, Biruni University Hospital
  • Éducation

    MSc Faculté de Médecine (ING) Université Hacettepe 1991-1997
    Département de spécialisation en pédiatrie, Université de Dicle, 1997-2002
    Faculté de médecine mineure Cerrahpaşa Département d'hématologie et d'oncologie pédiatriques Université d'Istanbul 2006-2009
    Unité de transplantation de moelle osseuse Hôpital MP Göztepe 2012-2013

    Expérience

    Professeur adjoint
    Université d'Afyon Kocatepe/Faculté de médecine/Sciences médicales internes
    2003-2009 Département/Département de Pédiatrie)

    Professeur adjoint
    Université d'Istanbul/Faculté de médecine Cerrahpaşa/Sciences médicales internes
    2006-2009 Département de Pédiatrie

    Spécialiste en hématologie pédiatrique, Hôpital pour enfants de Diyarbakır, service obligatoire en hématologie pédiatrique 2009-2012
    Transfert Ünitesi Assistant Spécialiste en Hématologie Hôpital Privé Medical Park Göztepe Unité de Transplantation de Moelle Osseuse Assistant Responsable Spécialiste en Hématologie Pédiatrique
    2012-2013

    Professeur adjoint
    Université d'Akdeniz / Faculté de médecine / Département des sciences médicales internes (Département de pédiatrie)
    2013-2014

    Professeur adjoint (Université de Marmara/Faculté de médecine/Département des sciences médicales internes/Département de pédiatrie) 2014-2024

    Adhésions scientifiques

    Société turque d'hématologie
    Association turque d'hématologie pédiatrique
    Association Pédiatrique de Marmara
    Société turque de pédiatrie
    Chambre médicale d'Istanbul
    EBMT (Transplantation européenne de moelle osseuse)

  • Lire la suite
Tomothérapie
$8,440 - $14,140
Curiethérapie
$10,000 - $12,000
Info